J Korean Diabetes.  2013 Sep;14(3):125-127. 10.4093/jkd.2013.14.3.125.

Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues

Affiliations
  • 1Department of Internal Medicine, Division of Endocrinology and Metabolism, The Catholic University of Korea, Seoul, Korea. drkwon@catholic.ac.kr

Abstract

Recently, incretin hormone-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become the main therapeutic tools in the hyperglycemia management in patients with type 2 diabetes mellitus. These therapeutic agents could fill an important gap in glycemic control for patients with type 2 diabetes because the incretin response is blunted in type 2 diabetes mellitus. GLP-1 analogues can be classified as exendin-4 backbone (Exenatide, Exenatide LAR and Lixisenatide) and human GLP-1 backbone (Liraglutide, Taspoglutide and Albiglutide). Among these, Exenatide, Exenatide LAR and Liraglutide are currently available. This review will focus on the clinical efficacies of GLP-1 analogues in glycemic control for patients with diabetes.

Keyword

Type 2 diabetes mellitus; GLP-1 analogues; Incretins

MeSH Terms

Diabetes Mellitus, Type 2
Glucagon
Glucagon-Like Peptide 1
Humans
Hyperglycemia
Incretins
Peptides
Venoms
Liraglutide
Glucagon
Glucagon-Like Peptide 1
Incretins
Peptides
Venoms
Full Text Links
  • JKD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error